Licensing status

Publication and contact information

Drug platforms

N-Glycosylation of Fc regions to improve antibody half-life and specificity

In vitro studies yielded a monomeric Fc fragment of IgG that could help extend antibody half-life and decrease off-target effects. N-Glycosylation of the IgG Fc fragment at two sites in the dimeric binding domain prevented dimerization, which could help decrease the risk of off-target effects caused by bivalent antibodies. In mice, a Fab fused with a tandem repeat of monomeric Fc fragments had a threefold longer half-life than a Fab fused with a single monomeric Fc fragment. Next steps could include designing therapeutic antibodies that incorporate monomeric Fc fragment repeats.

SciBX 6(20); doi:10.1038/scibx.2013.503
Published online May 23, 2013

Patent and licensing status unavailable

Ishino, T. et al. J. Biol. Chem.; published online April 24, 2013;
Contact: Tetsuya Ishino, Pfizer Inc., Cambridge, Mass.